Company intelligence / Profile preview

Lirum Therapeutics

New York, NY, United Stateslirumtx.com ↗

Ownership: Private
Employees: ~3
Development stage: Phase 1

Overview

LX-101 has been evaluated in Phase 1a trials in patients with advanced, pretreated cancer where it was found to be well-tolerated and demonstrated single agent activity. Recent data shows LX-101's ability to inhibit TED-derived orbital fibroblasts, decrease inflammatory cytokines, reduce pro-fibrotic components, and modulate TED-derived T-cells.

Therapeutic areas: OncologyImmunology
Modalities: Targeted therapyPrecision-engineered targeted therapyPayload-bearing targeted therapy
Industry: Biotech

Drug pipeline

1 asset

LX-101

Phase 1

Indications: Thyroid eye disease, Pediatric sarcomas, Oncology, Autoimmune diseases

Beyond the preview

Go deeper on Lirum Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lirum Therapeutics.

Explore the full profile